目的 评估复方皂矾丸、罗沙司他胶囊两种药物联合应用对肾性贫血患者的综合获益。方法 采用回顾性队列分析纳入2023年5月—2025年5月贵州医科大学附属医院收治的80例肾性贫血患者作为研究对象，依据治疗方法不同分对照组（40例）和治疗组（40例）。对照组给予罗沙司他胶囊口服，身体质量45～60 kg服药剂量为100 mg/次；≥60 kg者服药剂量为120 mg/次，3次/周。治疗组在对照组基础上给予复方皂矾丸口服，9丸/次，3次/d。两组患者均治疗3个月。观察两组的临床疗效，比较红细胞（RBC）计数、血红蛋白（Hb）、转铁蛋白饱和度（TSAT）、铁蛋白（SF）、转铁蛋白（TRF）水平及免疫相关指标的变化情况。结果 治疗后，治疗组患者总有效率是97.50%，较对照组总有效率77.50%显著提高（P＜0.05）。治疗后，两组RBC、Hb水平均较同组治疗前显著升高（P＜0.05）；治疗后，治疗组RBC、Hb水平较对照组高（P＜0.05）。治疗后，两组TSAT、SF、TRF水平较前显著升高（P＜0.05）；治疗后，治疗组TSAT、SF、TRF水平均较对照组高（P＜0.05）。治疗后，两组CD3⁺、CD4⁺、CD4⁺/CD8⁺显著升高，CD8⁺降低（P＜0.05）；治疗后，治疗组CD3⁺、CD4⁺、CD4⁺/CD8⁺高于对照组，CD8⁺较对照组低（P＜0.05）。结论 复方皂矾丸联合罗沙司他胶囊治疗肾性贫血患者可显著提高临床疗效，纠正贫血状态，改善铁代谢与免疫功能，且安全性尚可，可在临床推广。

Objective To evaluate the comprehensive benefits of combined application of Zaofan Pills combined with roxadustat in treatment of renal anemia. Methods A retrospective cohort analysis was conducted to include 80 patients with renal anemia who were admitted to the Affiliated Hospital of Guizhou Medical University from May 2023 to May 2025 as the research subjects. They were divided into control group (40 cases) and treatment group (40 cases) based on different treatment methods. Patients in control group were given Roxadustat Capsules for oral administration, for patients with body weight of 45 to 60 kg, the dosage was 100 mg per time, for those weighing 60 kg or more, the dosage was 120 mg per time, three times a week. Patients in treatment group were given Compound Zaofan Pills for oral administration, 9 pills per time, three times daily. Both groups were treated for 3 months. The clinical efficacy of two groups was observed, the changes in RBC count, Hb, TSAT, SF, TRF levels, and immune-related indicators were compared. Results After treatment, the total effective rate of the treatment group was 97.50%, which was significantly higher than that of the control group (77.50%, P < 0.05). After treatment, the levels of RBC and Hb in both groups were significantly higher than those before treatment in the same group (P < 0.05). After treatment, the levels of RBC and Hb in the treatment group were higher than those in the control group (P < 0.05). After treatment, the levels of TSAT, SF, and TRF in both groups were significantly higher than before (P < 0.05). After treatment, the levels of TSAT, SF, and TRF in treatment group were higher than those in control group (P < 0.05). After treatment, the levels of CD3⁺, CD4⁺, and CD4⁺/CD8⁺ in both groups significantly increased, while CD8⁺ decreased (P < 0.05). After treatment, the levels of CD3⁺, CD4⁺, and CD4⁺/CD8⁺ in the treatment group were higher than those in the control group, and CD8⁺ was lower than that in the control group (P < 0.05). Conclusion The combination of Compound Zaofan Pills combined with roxadustat in treatment of patients with renal anemia can significantly improve the clinical efficacy, correct the anemia condition, improve iron metabolism and immune function, and has acceptable safety. It can be promoted in clinical practice.

R977

贵州省卫生计划健康委科技项目（g2wkj2025-275）